{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:10:46Z","timestamp":1792001446041,"version":"4.4.0"},"reference-count":71,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T00:00:00Z","timestamp":1138060800000},"content-version":"vor","delay-in-days":1241,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>:<\/jats:bold>Since its initial description in 1955, primary aldosteronism was thought to be a rare cause of hypertension. However, improved screening methods show that primary aldosteronism is a common form of secondary hypertension. Diagnosis of this disorder results in improved or cured hypertension or targeted pharmacotherapy. Patients with hypertension and hypokalemia and most patients with treatment\u2010resistant hypertension should undergo screening for primary aldosteronism. A random and ambulatory ratio of plasma aldosterone concentration (PAC) to plasma renin activity (PRA) that is elevated and a PAC higher than a set cutoff is a positive screen for primary aldosteronism. An increased PAC\/PRA ratio alone is not diagnostic of primary aldosteronism; primary aldosteronism must be confirmed by demonstrating inappropriate aldosterone secretion with either the intravenous saline suppression test or measurement of 24\u2010hr urinary aldosterone while the patient is on a high\u2010sodium diet. The two major subtypes of primary aldosteronism are unilateral aldosterone\u2010producing adenoma (APA) and bilateral idiopathic hyperplasia (IHA). Patients with APA are usually treated with unilateral adrenalectomy, and patients with IHA are treated medically. The subtype evaluation may require one or more tests, the first of which is imaging the adrenals with computerized tomography (CT). When a solitary unilateral macroadenoma (&gt; 1 cm) and normal contralateral adrenal morphologic pattern are found on CT in a young patient with primary aldosteronism, unilateral laparoscopic adrenalectomy is a reasonable therapeutic option. However, in many cases, CT imaging may reveal normal\u2010appearing adrenals or ambiguous findings. Adrenal venous sampling helps to resolve these clinical dilemmas.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2002.tb04413.x","type":"journal-article","created":{"date-parts":[[2009,7,9]],"date-time":"2009-07-09T18:38:20Z","timestamp":1247164700000},"page":"61-76","source":"Crossref","is-referenced-by-count":67,"title":["Primary Aldosteronism"],"prefix":"10.1111","volume":"970","author":[{"suffix":"Jr.","given":"WILLIAM F.","family":"YOUNG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,24]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"3","article-title":"Presidential address: Part I","volume":"45","author":"Conn J.W.","year":"1955","journal-title":"Painting background; Part II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.8.2854"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045415-199907000-00012"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-001-0045-3"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/1043-2760(94)90090-6"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812173392507"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/3.7.576"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","unstructured":"Lifton R.P. R.G. Dluhy M. Powers et al.1992. A chimaeric 11\u03b2\u2010hydroxylase\/aldosterone synthase gene causes glucocorticoid\u2010remediable aldosteronism and human hypertension. Nature 355: 262\u2010265.","DOI":"10.1038\/355262a0"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-200107000-00003"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.20.85"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.6.1471"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.29.3.723"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199512010-00054"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002083220601"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-000-0017-z"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70298-2"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90786-1"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-10-813"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(01)80117-7"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1981.00340130033011"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-5-952"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1996.tb00600.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.5.1863"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1993.tb01687.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1985.tb02641.x"},{"key":"e_1_2_5_28_2","first-page":"17","article-title":"[Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients.]","volume":"45","author":"Kreze A.","year":"1999","journal-title":"Vnitr. Lek."},{"key":"e_1_2_5_29_2","first-page":"731","article-title":"Screening of a population of young hypertensives for primary hyperaldosteronism","volume":"8","author":"Kumar A.","year":"1994","journal-title":"J. Hum. Hypertens."},{"key":"e_1_2_5_30_2","first-page":"200","article-title":"[Incidence of primary hyperaldosteronism in hospitalized hypertensive patients.]","volume":"100","author":"Lazurova I.","year":"1999","journal-title":"Bratisl. Lek. Listy."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001013"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)74868-6"},{"key":"e_1_2_5_33_2","first-page":"800","article-title":"[High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension.]","volume":"127","author":"Mosso L.","year":"1999","journal-title":"Rev. Med. Chile."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00608.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","unstructured":"Montori V.M. & W.F. Young Jr. 2002. Use of plasma aldosterone concentration\u2010to\u2010plasma renin Aactivity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol. Metab. Clin. N. Amer. In press.","DOI":"10.1016\/S0889-8529(02)00013-0"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00060793-200106000-00004"},{"key":"e_1_2_5_37_2","first-page":"941","article-title":"Primary aldosteronism: are we diagnosing and operating too few patients? World J","volume":"25","author":"Gordon R.D.","year":"2001","journal-title":"Surg."},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.9.877"},{"key":"e_1_2_5_39_2","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1210\/jcem.86.9.7867","article-title":"Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone\u2010producing adenoma in low renin hypertensives","volume":"86","author":"Hirohara D.","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"e_1_2_5_40_2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.1993.00410180075008","article-title":"The diagnosis of primary aldosteronism and separation of two major subtypes","volume":"153","author":"Weinberger M.H.","year":"1993","journal-title":"Arch. Int. Med."},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30425-0"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.6.5.717"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)91022-7"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-4-200108210-00010"},{"key":"e_1_2_5_45_2","first-page":"460","article-title":"Incidentally discovered adrenal masses","volume":"16","author":"Kloos R.T.","year":"1995","journal-title":"Endocr. Rev."},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-11-199412010-00010"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(96)80033-X"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.3.1066"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-200109000-00003"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-33-4-713"},{"key":"e_1_2_5_51_2","first-page":"321","article-title":"Adrenal scintiscanning with NP\u201059, a new radioiodinated cholesterol agent","volume":"54","author":"Miles J.M.","year":"1979","journal-title":"Mayo. Clin. Proc."},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197602192940802"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-4-825"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-36-2-401"},{"key":"e_1_2_5_55_2","first-page":"576","article-title":"Correctable subsets of primary aldosteronism","volume":"3","author":"Irony I.","year":"1990","journal-title":"Primary adrenal hyperplasia and renin responsive adenoma. Am. J. Hypertens."},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(78)90161-9"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-49-1-87"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-1-67"},{"key":"e_1_2_5_59_2","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1210\/jcem.85.12.7086","article-title":"Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone\u2010producing adenoma","volume":"85","author":"Phillips J.L.","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.31.1.445"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.5.1507"},{"key":"e_1_2_5_62_2","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1210\/jcem.83.7.4946","article-title":"Diagnosis of glucocorticoid\u2010remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene","volume":"83","author":"Mulatero P.","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1997.tb00999.x"},{"key":"e_1_2_5_64_2","unstructured":"Gordon R.D. D.J. Torpy A.R. Lafferty et al.1999. Familial hyperaldosteronism type II (FH\u2010II) [abstract #S55\u20102].InProgram and Abstracts of 81st Annual Meeting of the Endocrine Society. San Diego.: 54."},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.9.3214"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.37.11.831"},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1996.86210.x"},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200103000-00001"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(97)90218-X"},{"key":"e_1_2_5_70_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy\u2010spironolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"Gasparo M.","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_5_71_2","first-page":"I\u201098","article-title":"Eplerenone, a novel and selective aldosterone receptor antagonist: efficacy in patients with mild to moderate hypertension","volume":"98","author":"Epstein M.","year":"1998","journal-title":"Circulation."},{"key":"e_1_2_5_72_2","first-page":"1059","article-title":"Mechanism of inhibition of aldosterone secretion by Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism","volume":"71","author":"Yokoyama T.","year":"1995","journal-title":"Nippon Naibunpi Gakkai Zasshi"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2002.tb04413.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2002.tb04413.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T21:26:11Z","timestamp":1739222771000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2002.tb04413.x"}},"subtitle":["Management Issues"],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1111\/j.1749-6632.2002.tb04413.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04413.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}